In preclinical studies, TST001 upregulated PD-L1 expression on low-to-medium CLDN18.2-positive tumor cells and demonstrated stronger ADCC, CDC, and antibody-dependent cellular phagocytosis (ADCP) activity than zolbetuximab [48]. The gene discussed is CD274; the disease is neoplasm.